About: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $26.50 (+2.44%)
NGNE NASDAQ Neurogene Inc
Neurogene Inc share price
NGNE price activity
Last Price
$26.500
Change (24hr)
0.63 USD (2.44%)
Volume
493.86K
Volume (4w avg)
-
Open
$28.00
Day Range
$26.24 - $28.97
Previous Close
$25.87
Last Trade
08 Oct, 8:22 pm GMT+0
Delayed
08 Oct, 8:22 pm GMT+0
NGNE price performance
Delayed
08 Oct, 8:22 pm GMT+0
NGNE Market Signals